AMG 655

Known as: AMG-655, AMG655 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
01220092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients have not seen any major therapeutic… (More)
Is this relevant?
2015
2015
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells while sparing normal tissues… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Oncogenic mutations of ras and B-raf frequently occur in many cancer types and are critical for cell transformation and… (More)
Is this relevant?
Review
2010
Review
2010
Conatumumab (AMG-655), under development by Amgen Inc and Japanese licensee Takeda Bio Development Center Ltd, is a fully human… (More)
Is this relevant?
2010
2010
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptors 4 and 5 (DR4, DR5) to transduce… (More)
Is this relevant?
2009
2009
Study design PFS (months) OS (months) Comments #4504 [4] Arm A: gemcitabine, Arm B: gemcitabine + cisplatin 3.9 vs. 3.8 (P=0.8) 8… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2009
2009
4130^ Introduction: Pmab is a fully human antibody targeting the epidermal growth factor receptor that is approved as monotherapy… (More)
Is this relevant?